Welcome to our dedicated page for Enlivex news (Ticker: ENLV), a resource for investors and traders seeking the latest updates and insights on Enlivex stock.
Enlivex Ltd. develops quality longevity therapeutics and operates a prediction markets treasury alongside its clinical programs. The company’s news centers on Allocetra™, a clinical-stage immunotherapy for inflammatory conditions associated with aging, with a primary focus on moderate-to-severe age-related knee osteoarthritis.
Recurring updates also cover the RAIN token and Rain protocol, including digital asset treasury holdings, exchange listings, decentralized prediction-market infrastructure, tokenized exposure to Enlivex ordinary shares, financial results affected by treasury assets, financing activity, and share repurchase authorization.
Enlivex (Nasdaq: ENLV) announced that its primary treasury asset, the RAIN token, was listed on Kraken effective February 9, 2026. The company says the listing expands token access and aims to enhance secondary market liquidity, price discovery, and accessibility for RAIN users and governance participants.
Kraken serves about 5.7 million users and reported over $2 trillion in 2025 trading volume, making it a major access point for institutional and retail digital-asset trading.
Enlivex (Nasdaq: ENLV) announced that its primary digital treasury asset, the RAIN token, was listed on the WhiteBIT cryptocurrency exchange effective January 21, 2026. The listing is intended to expand regional market access and improve secondary market liquidity for RAIN as part of Enlivex's digital asset treasury strategy. WhiteBIT is described as the largest European crypto exchange by traffic and is part of W Group, which serves more than 35 million customers globally. RAIN functions as the governance and utility token of a decentralized predictions and options protocol on the Arbitrum network that enables users to create, trade, and resolve markets tied to real-world events.
Enlivex Therapeutics (Nasdaq: ENLV) has initiated a voluntary delisting of its ordinary shares from the Tel Aviv Stock Exchange with the last TASE trading day expected to be April 23, 2026 and delisting effective on or about April 26, 2026. The company will continue to trade on Nasdaq under the symbol ENLV and will keep filing public reports with the SEC and Nasdaq.
The board approved the move to operate under a single set of listing requirements, reduce duplicative administrative costs, potentially enhance Nasdaq liquidity, and focus investor relations on U.S. capital markets.
Enlivex (Nasdaq: ENLV) announced that its treasury token RAIN began trading on the KuCoin exchange effective January 6, 2026. The listing places RAIN on a major global venue that serves more than 40 million users and ranks among the top ten cryptocurrency exchanges.
Company commentary says the KuCoin listing is expected to expand global market access and secondary liquidity for Enlivex's primary digital treasury holding. KuCoin offers spot trading, derivatives, and yield services and has a strong user base in Southeast Asia. RAIN is described as the governance and utility token of a decentralized predictions and options protocol on Arbitrum.
Enlivex (Nasdaq: ENLV) will host a virtual fireside chat on December 11, 2025 at 11:00 am ET. Executive Chairman Shai Novik will discuss the company’s plans after a $212,000,000 private placement, including a new digital asset treasury strategy focused on RAIN token accumulation, and updates on advancing clinical development of Allocetra. The event includes a live Q&A and a recorded webcast to be posted on the company’s investor relations site. Investors may submit questions in advance to Enlivex@KCSA.com and must register via the provided link.
Enlivex (Nasdaq and TASE: ENLV) announced the closing of a $212,000,000 private placement on November 26, 2025. The company said it will use net proceeds to implement the world’s first RAIN prediction markets token digital-asset treasury strategy while continuing core operations.
RAIN is described as a decentralized predictions and options protocol on Arbitrum with AI-resolved outcomes and a deflationary Buyback & Burn governance token. The company also appointed Matteo Renzi, former Italian prime minister, to its board of directors. BTIG served as sole placement agent.
Enlivex (NASDAQ: ENLV) announced a $212,000,000 private placement of 212,000,000 ordinary shares at $1.00 per share (an 11.5% premium to the Nov 21, 2025 close), funded in a combination of USD and USDT, with proceeds intended to implement a RAIN prediction‑markets token treasury strategy while continuing core clinical work. The company also announced the appointment of Matteo Renzi, former prime minister of Italy, to the Enlivex board effective November 24, 2025. RAIN is described as a decentralized prediction and options protocol on the Arbitrum network with AI‑resolved markets and a buyback & burn token mechanism.
Enlivex (Nasdaq: ENLV) announced a $212,000,000 PIPE to sell 212,000,000 shares at $1.00 per share (an 11.5% premium to the Nov 21, 2025 close), funded in a combination of USD and USDT.
Proceeds are intended to implement the first RAIN prediction markets token treasury strategy via RAIN token accumulation while the company continues clinical development of Allocetra for knee osteoarthritis. Former Italian prime minister Matteo Renzi will join the board following closing. The closing is expected on or before November 25, 2025, subject to customary conditions. BTIG is sole placement agent.
Enlivex (Nasdaq: ENLV) announced positive six-month topline Phase IIa data for Allocetra in patients with age-related primary moderate-to-severe knee osteoarthritis.
Key findings: durable pain and function improvement versus placebo in the 60+ population (3-month composite: -26.8 vs -13.4, p=0.008; 6-month composite at 61+: -27.8 vs -15.5, p=0.02). The company reported a favorable safety profile through six months and plans a Phase IIb trial to start in H1 2026.
Enlivex Therapeutics (Nasdaq: ENLV) will present Phase IIa 3-month topline data for Allocetra in moderate-to-severe knee osteoarthritis (KOA) at ACR Convergence 2025 on October 28, 2025.
The late-breaking poster reports clinically meaningful and statistically significant pain reduction and function improvement versus placebo in idiopathic age-related KOA patients (≥60 years), who represent >50% of the KOA market and 54% of the study population, and includes new supporting biomarker data.
Poster title: Randomized, Double-Blind, Placebo-Controlled Phase IIa Trial (NCT06233474). Presentation by Prof. Philip Conaghan; Einat Galamidi, MD, CMO, available for meetings.